Customs duty waive off on Remdesivir will further augment domestic availability: Sadananda Gowda

The Minister had earlier asked the State governments to take strict action against anyone found indulged in black marketing or hoarding of Remdesivir.

April 21, 2021 01:08 pm | Updated 01:13 pm IST - New Delhi:

 D.V. Sadananda Gowda. File

D.V. Sadananda Gowda. File

The government’s decision to waive off customs duty on antiviral drug Remdesivir would help in augmenting the supply of the medicine in the wake of soaring COVID-19 cases in the country, Chemicals and Fertilizers Minister Sadananda Gowda said on Wednesday.

The government on Tuesday waived off all customs duty on imported Remdesivir injections and the drug’s active pharmaceutical ingredients (API) in order to boost supplies.

There is already a ban on the export of the Remdesivir injection from the country. “Considering the immediate requirement on the recommendation of the Department of Pharmaceuticals, the Department of Revenue has reduced customs duty on #Remdesivir and its API/KSM. This step will further augment domestic availability of Remdesivir injection,” Mr. Gowda said in a tweet.

The Minister had earlier asked the State governments to take strict action against anyone found indulged in black marketing or hoarding of Remdesivir.

Black marketing, hoarding of Remdesivir is being strictly monitored and State governments have been advised to take strict action against those indulging in such malpractices, he had tweeted.

On Sunday, Minister of State of Chemicals and Fertilizers Mansukh L Mandaviya had tweeted that the government plans to double the production of Remdesivir to around three lakh vials per day over the next 15 days, to make it available readily for the treatment of COVID-19 .

The government has given permission to 20 plants to produce the antiviral drug, he had said. Already, Remdesivir is being rolled out of 20 plants in the country.

On Saturday, the National Pharmaceutical Pricing Authority (NPPA) had announced that the pharmaceutical companies such as Cadila Healthcare, Dr. Reddy’s Laboratories and Cipla have reduced the price of their respective brands of Remdesivir injection (100mg/vial).

Nearly three lakh new COVID-19 cases and over 2,000 deaths were reported in the country on Wednesday, a record-high since the pandemic broke out last year.

As per the Union Health Ministry, as many as 2,95,041 new COVID-19 cases and 2,023 deaths were reported, taking the total cases to 1,56,16,130, including 21,57,538 active cases.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.